Beating type 2 diabetes into remission by McCombie L et al.
Beating type 2 diabetes into remission
Recognising and accurately coding reversal of type 2 diabetes is key to improving outcomes and
reducing healthcare costs, argue Louise McCombie and colleagues
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Type 2 diabetes, generally perceived as progressive and
incurable, now affects 5-10% of the population, about 3.2
million people in the UK.1 Until complications develop, most
patients are managed entirely within primary care, with diabetes
comprising a major part of general practice activity. About 10%
of total UK NHS expenditure goes on treating diabetes, and
international figures suggest that medical costs for people with
diabetes are twofold to threefold greater than the average for
age and sex matched people without diabetes.1
Application of current clinical guidelines to reduce glycated
haemoglobin (HbA1c) levels and cardiovascular risks, primarily
with drugs and generic lifestyle advice, has improved clinical
outcomes, but many patients still develop vascular
complications, and life expectancy remains up to six years
shorter than in people without diabetes.2 The diagnosis carries
important social and financial penalties for individuals, as well
as poor health prospects.
Remission of diabetes (no longer having diabetes, at least for a
period) is clearly attainable for some, possibly many, patients
but is currently very rarely achieved or recorded. Greater
awareness, documentation, and surveillance of remissions should
improve health outcomes and reduce healthcare costs.
Changing management
In keeping with trends in most medical specialties, diabetes
management is beginning to focus on reversible underlying
disease mechanisms rather than treating symptoms and
subsequent multisystem pathological consequences.3 4 Both
(epi)genetic predisposition and ageing have a role in type 2
diabetes, but it is rare without weight gain.
Lowering blood glucose or HbA1c concentrations remains the
primary aim of management, as reflected in current clinical
guidelines and the actions of licensed drugs. However,
management and guidelines focus on use of antidiabetes drugs,
with only lip service paid to diet and lifestyle advice. The scale
of the market for drug therapies, and their likely inadequacy, is
illustrated by the fact that 488 drugs (excluding insulins) are
currently licensed worldwide to treat type 2 diabetes, with 70
generic compounds.5 They all lower blood glucose and HbA1c
significantly, but no trials have yet examined drugs administered
together with optimal diet and lifestyle advice for weight control.
In contrast, consistent evidence shows that weight loss is
associated with extended life expectancy for people with
diabetes, and that weight loss of around 15 kg often produces
total biochemical remission of type 2 diabetes, restoring beta
cell function.6 7 Recognition that accumulation of ectopic fat in
the liver and pancreas impairs organ function to cause type 2
diabetes, but is reversible, has raised awareness that remission
is possible.7 Media attention has encouraged increasing numbers
of people with type 2 diabetes to lose weight and shed the
diagnosis. Remission produces a strong sense of personal
achievement and empowerment; it also benefits medical systems
because patients no longer require antidiabetes drugs. The UK
NHS currently spends almost £1bn (€1bn; $1.3bn) a year (£22m
a day) on antidiabetes drugs, and costs are rising worldwide as
diabetes rates and drug prices escalate.
Criteria for remission of diabetes
There is no consensus on the criteria for remission of diabetes.
The published criteria, and thus reported remission rates, vary,
but all require being below the World Health
Organization/American Diabetes Association (ADA) diagnostic
thresholds for diabetes (table 1⇓). Most recent publications,
including the large Look AHEAD trial of lifestyle
interventions,10 refer to an ADA consensus group statement8
that defined test results below the diagnostic threshold for
diabetes as partial remission and remission of “pre-diabetes” as
complete remission.
However, using the term partial remission does not fully portray
the logic or importance of becoming non-diabetic to patients.
Although remission of prediabetes is desirable because it reduces
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cardiovascular risk, that routine management should aim to help
patients escape the diagnostic category of diabetes, with its
personal burdens and risks of microvascular disease. That
requires using the WHO diagnostic thresholds for diabetes to
establish remission and accepting that some patients will
continue to have impaired glucose tolerance or prediabetic
fasting glucose and HbA1c profiles.
8 Measurement of either
HbA1c or blood glucose is sufficient to identify remission. To
avoid misclassification resulting from measurement error or
biological variation, we recommend that patients should have
two tests results (usually HbA1c) below the diagnostic threshold,
at least two months apart to confirm remission. This reflects
about four months of normoglycaemia. Patients in remission
should be kept under regular review with annual testing (table
1⇓).
Potential metabolic value of remission
Clinical outcomes for people with type 2 diabetes are all worse
at higher glucose or HbA1c concentrations.
10 No study has yet
reported outcomes for people who achieve remission, but good
glycaemic control through drug treatment improves
microvascular outcomes (retinopathy, neuropathy, nephropathy)
in both type 1 and type 2 diabetes.11 Reduced cardiac events
have also been observed in patients with type 2 diabetes after
bariatric surgery.12 In contrast, some drug trials have indicated
increased mortality when HbA1c approaches normal levels,
probably through hypoglycaemia provoking arrhythmias.13 Look
AHEAD, a trial of lifestyle intervention in patients with mean
diabetes duration of five years, reported 11.5% remission at 12
months with 8.6% weight loss, but that proportion fell by about
30% annually.10 Health outcomes of participants have not yet
been reported, but the limited evidence and first principles
suggest that remission of diabetes (without antidiabetes drugs)
should enhance overall prognosis, becoming a primary
management target as early as possible after diagnosis.10
Coding for health records
Remission of type 2 diabetes can be inferred from routine
records of patients labelled diabetic who have non-diabetic
biochemical test results (usually HbA1c<48 mmol/mol), when
there is no record that antidiabetes drugs are prescribed.14 In the
UK, clinicians have used Read codes to record patients’ findings
and procedures since 198515 but are now converting to the
international SNOMED system. The basic coding framework
will remain, however.
The Read code dictionary includes codes 21263 or 212H for
“diabetes resolved” and C10P for “diabetes in remission.”
Diabetes resolved is used for patients misdiagnosed with
diabetes or in whom diabetes was secondary to a factor that has
since been removed, such as withdrawal of steroid treatment.
Such patients do not require annual reviews or surveillance.
Code C10P should be used for patients who have achieved
remission of type 2 diabetes, usually by substantial weight loss.
These patients may be considered non-diabetic for matters such
as insurance, driving, or employment but as the code is
diagnostic they will remain scheduled for annual reviews and
retinal screening programmes.
Achieving remission
In the few countries with data, patients are seldom recorded as
having diabetes in remission. Karter and colleagues found
remissions in only 0.14% of 120 000 US patients followed for
seven years.14 The Scottish Care Information Diabetes database,
which includes every patient in Scotland, shows that less than
0.1% of those with type 2 diabetes (245/254 208) were coded
as being in remission in March 2017 (table 2⇓).
Lack of agreed criteria and guidance over recoding may have
led to hesitation in coding remission, but the main reason for
the low recording is probably that few patients are attempting
or achieving remission. Patients and doctors may be unaware
that type 2 diabetes can be reversed, despite recent publicity.
The feasibility of sustained substantial intentional dietary weight
loss is widely doubted, despite publications of structured
approaches using an initial formula diet replacement to achieve
rapid substantial weight loss and then maintain 12-15 kg loss
at 12 months and beyond.16 17
The 2010 guideline of the Scottish Intercollegiate Guidelines
Network recommends sustained weight loss above 10% of body
weight or 15 kg for people with severe and complicated obesity,
including type 2 diabetes.18 This is difficult to achieve, even
with bariatric surgery, and only 75-80% of patients who succeed
are rewarded with diabetes remission.9
The drivers and barriers to successful remission are not fully
evaluated but are likely to include age, body mass index,
duration of diabetes, HbA1c concentrations, and drug treatment.
10
Physical and social environments, emotional states, and self
regulatory skills are important factors affecting adherence to a
weight management intervention.19 It is unknown whether the
degree of weight loss needed to achieve remission will be the
same for Asian people, who commonly develop type 2 diabetes
at a lower body mass index than people of European origin, but
probably with similar body fat content.
Doctors may be understandably reluctant to redefine a patient
as “in remission” if they are concerned that the remission,
dependent on maintaining weight loss, may not persist, and that
routine recall for annual checks might cease. However, under
the remission coding annual reviews and screening recalls will
continue. Another UK specific factor may have been fear of
losing the incentive payments for managing diabetes under the
Quality and Outcomes Framework (QOF). Again, coding
“diabetes in remission” retains the diagnostic status so the
practice payment would continue.
Diabetes in remission has not been specifically rewarded as a
management target in QOF. Incentives have been shown to
improve care and risk factors in other areas such as asthma and
cardiovascular disease. Forthcoming revisions of QOF in NHS
England, and its replacement in NHS Scotland, provide
opportunities to include diabetes remission as an incentivised
target.
Benefits of remission
Achieving remission has health benefits for patients and removes
the burden of daily monitoring and treatment, but correct coding
of remission has multiple further benefits. It removes the stigma
of having diabetes and provides a sense of personal achievement
and social status (box 1).
Diabetes is expensive, both for individuals and for health
systems. Evidence is needed on health demands and survival
after remission, but the demands are likely to be lower. The
average annual medical costs of type 2 diabetes in the US were
calculated at $6414 (£5000; €5400) in 2007, rising with age to
$9061 aged over 64,20 around 2.5 times greater than for people
without diabetes.21
The costs are climbing as expensive new drugs are launched,
under pharmacocentric clinical guidelines. In the UK these rising
costs are borne by the NHS. In other countries, costs fall to the
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2017;358:j4030 doi: 10.1136/bmj.j4030 (Published 2017 September 13) Page 2 of 6
ANALYSIS
 o
n
 23 Novem
ber 2018 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.j4030 on 13 September 2017. Downloaded from 
Box 1: Benefits of coding remission of diabetes
For patients
• Removes personal and social stigmatisation as diseased or “diabetic”
• Provides a target and a reward for the sustained hard work usually necessary to achieve and maintain substantial weight loss
• May permit life insurance, mortgages, travel insurance, etc without the higher premiums added for people with a diagnosis of type 2
diabetes
• Removes some occupational restrictions
For epidemiology and health systems
• Identifies a valuable indicator of success in healthcare, through national disease register monitoring
• Allows better analysis of long term morbidity and mortality risks
• Improves resource requirement forecasting
individual. Private health insurance will not usually cover
existing diabetes, presenting a barrier to optimal medical care.
Thus significantly more US adults with diabetes, and the
majority aged over 65, rely on public insurance such as
Medicare. The American Diabetes Association provides
indicative costs of Medicare cover for people with diabetes.
Annual premiums are around $1200 plus (optionally) $166 to
allow about half of prescription drug costs to be covered.
Prescription costs are not full covered until an individual has
spent over $4950 on drugs in a year.22 The 2009 US National
Health Interview Survey found that, depending on total
household income, people aged 18-64 with diabetes spend about
$3000 a year on private health insurance premiums, or
$2000-$6000 a year on healthcare (of poorer quality) if they do
not have health insurance.23
Other types of insurance are also more expensive. Life assurance
premiums are commonly doubled for people with diabetes,
adding around £600 a year to an average policy. The
international online insurance broker moneysupermarket.com
currently offers people with type 2 diabetes equivalent travel
policies at almost double the price of that for a person without
medical problems, adding £20-£30 to the cost of 14 days’ cover
in the US, or more if insulin is needed. At present, people who
have diabetes in remission are included in the cheaper category
(as are people with prediabetes). Awareness of tangible cost
savings of this kind might help maintain weight loss and
remission of type 2 diabetes: the promise of rewards and praise
for goals achieved are key elements in behaviour change
strategy.
Moving forward
It is in everybody’s interest to reclassify people with type 2
diabetes when they become non-diabetic. Official guidelines
and international consensus for recording diabetes in remission
are needed. We have proposed that two non-diabetic test results,
at least two months apart, should be required, with annual
reviews of HbA1c to confirm continuation (table 1⇓). The
appropriate interval between tests for establishing remission is
open to debate. It must be long enough to eliminate people with
temporary dips in glycaemia but short enough for patients to
maintain motivation. Having agreed criteria for coding diabetes
in remission (C10P in the UK) in record systems will benefit
patients and healthcare planning. Appropriate coding will make
it possible to monitor progress in achieving remission of type
2 diabetes nationally and internationally and to improve
predictions of long term health outcomes for patients with a
known duration of remission.
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Key messages
Remission of type 2 diabetes is achievable through substantial weight loss but is rarely recorded and probably under-reported
Recognising remission of diabetes can be a powerful motivator for patients to maintain weight loss
Diagnostic coding of “diabetes in remission” alleviates the social and financial penalties of diagnosis for patients while continuing medical
surveillance
Correct coding provides a valuable indication of healthcare success and can inform healthcare planning
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Tables
Table 1| Published and proposed criteria for diabetes in remission
ConfirmationCriteria for remission
Maintained for 1 yearPartial remission (no longer having diabetes): Both HbA
1c
 < 6.5% (<48 mmol/mol)
and fasting blood glucose 5.6-6.9 mmol/L without antidiabetes drugs (time not specified)
ADA Consensus Group8
Maintained for 1 yearComplete remission (no longer having prediabetes): Both HbA
1c
< 6% (<42
mmol/mol) and fasting blood glucose <5.6 mmol/L without antidiabetes drugs (time
not specified)
NoneHbA
1c
 < 6% (42 mmol/mol) or fasting blood glucose<5.6 mmol/L without antidiabetic
drugs (time not specified)
Buchwald et al9 (systematic review
after bariatric surgery)
Two non-diabetic test results, at least 2
months apart then reviewed annually
Previous diagnosis of type 2 diabetes by WHO criteria. HbA
1c
 <6.5% (<48 mmol/mol)
or fasting blood glucose<7 mmol/L and 2 hour glucose<11 mmol/L after at least 2
months without antidiabetes medication
Authors’
proposal for coding in routine
practice
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Table 2| Numbers of people in Scotland with different coding categories registered in the SCI Diabetes database (March 2017)
No of patientsDiabetes category
30 568DD-DMT-01 Type 1 diabetes mellitus 
254 208DD-DMT-02 Type 2 diabetes mellitus 
20DD-DMT-03 Current gestational diabetes 
212DD-DMT-04 Maturity onset diabetes of youth
196DD-DMT-05 Latent autoimmune diabetes of adulthood 
12DD-DMT-06 Maternally inherited diabetes and deafness 
9DD-DMT-07 Neonatal diabetes
392DD-DMT-08 Secondary—pancreatic pathology 
242DD-DMT-09 Secondary—drug induced 
105DD-DMT-10 Secondary—disease 
657DD-DMT-11 Impaired glucose tolerance
209DD-DMT-12 Impaired fasting glucose 
24DD-DMT-13 History of gestational diabetes
23DD-DMT-14 Stress induced hyperglycaemia (transitory) 
587DD-DMT-15 Diabetes resolved 
665DD-DMT-16 Not diabetic 
245DD-DMT-17 Diabetes in remission 
432Dd-Dmt-98 Other type of diabetes 
1437DD-DMT-99 Not known
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